At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 50 target

Drug / intervention

Bleomycin sulfate +7 morebiological

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002715

NCT00002715Phase 2Completed

Compare CT.gov

A Phase II Pilot Study of Short Term (12 Week) Combination Chemotherapy (Stanford V) in Unfavorable Hodgkin's Disease

Stanford University·interventional·Posted Jan 27, 2003·Updated Aug 12, 2020

In Brief

A Phase 2 clinical trial evaluating Bleomycin sulfate, Stanford V regimen, and 6 other interventions for Lymphoma. Completed, enrolled 50 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsLymphoma

CountriesUnited States

CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished

198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartApr 1989

First PostedJan 2003

Primary CompletionJan 2007

Study CompletionOct 2015

TodayJul 2026

First PostedJan 27, 2003

Enrollment StartApr 1, 1989

Primary CompletionJan 1, 2007

Study CompletionOct 1, 2015

TodayJul 2, 2026

Enrollment to primary: 17.8 yearsPosted 23.4 years ago